Ophthalmic solution of difluprednate

Patent metadata

Field	Value
Publication number	US-11890375-B2
Application number	US-202117386935-A
Country	US
Kind code	B2
Filing date	Jul 28, 2021
Priority date	Oct 16, 2015
Publication date	Feb 6, 2024
Grant date	Feb 6, 2024

Abstract

The present invention provides a method of treatment of inflammatory disorder of the eye, said method comprising administering into the eye of a person in need thereof, an aqueous solution comprising difluprednate as the sole active ingredient at a concentration of 0.02% to 0.04% weight by volume in an aqueous vehicle, wherein the solution is free of oil and wherein the solution is administered twice-a-day. The present invention also provides an ophthalmic solution comprising a. therapeutically effective concentration of difluprednate, a crystal growth inhibitor and pharmaceutically acceptable amounts of a solubilizer comprising a mixture of i. quaternary ammonium compound and ii. polyethoxylated castor oil, b. in an aqueous vehicle. wherein the crystal growth inhibitor is polyvinyl alcohol or its derivatives.

First claim

The invention claimed is:

1. A clear ophthalmic aqueous solution comprising:
(a) about 0.04% w/v difluprednate;
(b) about 1.4% w/v polyvinyl alcohol or derivative thereof;
(c) about 0.025% w/v benzalkonium chloride; and
(d) about 5.0% w/v polyoxyl 35 castor oil.

2. The clear ophthalmic aqueous solution of claim 1 , wherein the solution further comprises a preservative, a chelating agent, a pH adjusting agent, a cosolvent, or a combination thereof.

3. The clear ophthalmic aqueous solution of claim 2 , wherein the preservative is selected from biguanide, boric acid, N-lauroyl sarcosine, sodium salt of N-lauroyl sarcosine, and combination thereof.

4. The clear ophthalmic aqueous solution of claim 2 , wherein the chelating agent is selected from edetate disodium, ethylenediamine tetracetic acid, edetic acid, disodium edetate dihydrate, diethylenetriamine pentaacetic acid, and combination thereof.

5. The clear ophthalmic aqueous solution of claim 2 , wherein the pH adjusting agent is selected from acetic acid, sodium acetate, tartaric acid, sodium tartrate, citric acid, sodium citrate, hydrochloric acid, sodium hydroxide, and combination thereof.

6. The clear ophthalmic aqueous solution of claim 2 , wherein the cosolvent is selected from glycerol, propylene glycol, ethylene glycol, polyethylene glycol, glycofurol, and combination thereof.

7. The clear ophthalmic aqueous solution of claim 2 , wherein the solution is formulated for twice-a-day administration into the eye of a person in need thereof.

8. The clear ophthalmic aqueous solution of claim 2 , wherein percent transmission of the solution is greater than 90%.

9. A method of treating an inflammatory disorder of the eye, said method comprising administering twice-a-day, a clear aqueous solution comprising in an aqueous vehicle:
(a) about 0.04% w/v difluprednate,
(b) about 1.4% w/v polyvinyl alcohol or derivative thereof,
(c) about 0.025% w/v benzalkonium chloride; and
(d) about 5.0% w/v polyoxyl 35 castor oil;

into the eye of a person in need thereof.

10. The method of claim 9 , wherein the clear aqueous solution further comprises a preservative, a chelating agent, a pH adjusting agent, a cosolvent, or combination thereof.

11. The method of claim 10 , wherein:
the preservative is selected from biguanide, boric acid, N-lauroyl sarcosine, sodium salt of N-lauroyl sarcosine, and combination thereof;
the chelating agent is selected from edetate disodium, ethylenediamine tetracetic acid, edetic acid, disodium edetate dihydrate, diethylenetriamine pentaacetic acid, and combination thereof;
the pH adjusting agent is selected from acetic acid, sodium acetate, tartaric acid, sodium tartrate, citric acid, sodium citrate, hydrochloric acid, sodium hydroxide, and combination thereof; and
the cosolvent is selected from glycerol, propylene glycol, ethylene glycol, polyethylene glycol, glycofurol, and combination thereof.

12. The method of claim 9 , wherein percent transmission of the clear aqueous solution is greater than 90%.

13. The method of claim 9 , wherein the inflammatory disorder of the eye is pain and inflammation associated with ocular surgery and/or acute anterior uveitis, endogenous anterior uveitis, chronic uveitis, or a combination thereof.

14. The method of claim 13 , wherein the inflammatory disorder of the eye is acute anterior uveitis or chronic uveitis.

15. A clear ophthalmic aqueous solution comprising:
(a) about 0.04% w/v difluprednate;
(b) about 1.4% w/v polyvinyl alcohol or derivative thereof;
(c) about 0.025% w/v benzalkonium chloride;
(d) about 5.0% w/v polyoxyl 35 castor oil;
(e) about 0.6% w/v boric acid;
(f) about 0.005% w/v polyhexamethylene biguanide;
(g) about 0.03% w/v N-lauroyl sarcosine or sodium salt thereof
(h) about 0.05% w/v disodium edetate; and
(i) about 1.5% w/v glycerol.

16. The clear ophthalmic aqueous solution of claim 15 , wherein the solution is formulated for twice-a-day administration into the eye of a person in need thereof.

17. The clear ophthalmic aqueous solution of claim 15 , wherein percent transmission of the solution is greater than 90%.

18. A method of treating an inflammatory disorder of the eye, said method comprising administering twice-a-day, a clear aqueous solution comprising in an aqueous vehicle:
(a) about 0.04% w/v difluprednate,
(b) about 1.4% w/v polyvinyl alcohol or derivative thereof,
(c) about 0.025% w/v benzalkonium chloride; and
(d) about 5.0% w/v polyoxyl 35 castor oil;
(e) about 0.6% w/v boric acid;
(f) about 0.005% w/v polyhexamethylene biguanide;
(g) about 0.03% w/v N-lauroyl sarcosine or sodium salt thereof;
(h) about 0.05% w/v disodium edetate; and
(i) about 1.5% w/v glycerol;

into the eye of a person in need thereof.

19. The method of claim 18 , wherein the inflammatory disorder of the eye is pain and inflammation associated with ocular surgery and/or acute anterior uveitis, endogenous anterior uveitis, chronic uveitis, or a combination thereof.

20. The method of claim 19 , wherein the inflammatory disorder of the eye is acute anterior uveitis or chronic uveitis.

21. The clear ophthalmic aqueous solution of claim 15 , further comprising:
(j) about 0.01% w/v sodium acetate; and
(k) about 0.005% w/v acetic acid.

22. The method of claim 18 , wherein the clear aqueous solution further comprises:
(j) about 0.01% w/v sodium acetate; and
(k) about 0.005% w/v acetic acid.

Assignees

• Sun Pharma Advanced Res Co Ltd

Inventors

• Khopade Ajay Jaysingh
• Halder Arindam
• Shah Ankit Shaileshkumar

Classifications

• A61K9/08 Primary

  Solutions {(composition of solutions A61K47/00)} · CPC title

• A61K9/0048

  Eye, e.g. artificial tears · CPC title

• A61K31/573 Primary

  substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone · CPC title

• A61K47/02

  Inorganic compounds · CPC title

• A61K47/186

  Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide · CPC title